• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Dermatology

Evening-dose immune checkpoint inhibitors were associated with worse survival outcomes

byKassandra McFarlaneandSze Wah Samuel Chan
November 22, 2021
in Dermatology, Oncology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Receiving at least 20% of infusions after 1630h was associated with decreased overall survival in patients treated with immune-checkpoint inhibitors for metastatic melanoma

2. Both progression-free survival and disease response were worse in patients receiving at least 20% of infusions after 1630h.

Evidence Rating Level: 2 (Good)

Study Rundown: The immune system has circadian rhythm variability, such that weaker responses are noted in the evening. This study examined the outcome on overall survival (OS), progression-free survival (PFS), and disease response in patients receiving checkpoint inhibitor infusion treatment for stage IV melanoma at different times of the day. Evening was considered to begin at 1630h. Patients receiving a minimum of 20% of their treatment after 1630h were found to have reduced OS, with 5 year OS rates for these patients at 49% as compared to 68% for patients who had less than 20% evening treatments. PFS at 1 year in patients with a greater number of evening infusions was 40%, compared with 56% for patients with fewer evening infusions. Additionally, there was a decreased rate of disease response for patients receiving more evening infusions compared to patients receiving less (22% vs. 34%). The most common adverse events associated with checkpoint inhibitor treatment were colitis, hepatitis, and hypophysitis. No deaths due to treatment were reported. Limitations to the study include the retrospective format, the exclusion of patients receiving less than 4 infusions, as well as restriction of the study to one site. Additionally, the study results may not be applicable in all clinical scenarios due to variation of treatment sequence and duration for each patient. Overall, patients with stage IV melanoma may benefit from daytime, rather than evening, infusions of immune checkpoint inhibitors.

Click to read the study in The Lancet Oncology

Click to read an accompanying editorial in The Lancet Oncology

RELATED REPORTS

#VisualAbstract: Adjuvant Dabrafenib plus Trametinib Improves Outcomes in Stage III Melanoma

#VisualAbstract: Neoadjuvant Nivolumab and Ipilimumab Improve Outcomes in Resectable Stage III Melanoma

Atezolizumab, Vemurafenib, and Cobimetinib in Melanoma With CNS Metastases

Relevant Reading: Circadian rhythms in adaptive immunity

In-Depth [retrospective cohort]: This retrospective cohort study based out of one site in the United States recruited 299 adult patients with stage IV melanoma who received at least 4 infusions of immune checkpoint inhibitor therapy (nivolumab, pembrolizumab, ipilimumab, or a combination). Total and 5 year overall survival (OS) were primary outcomes, with both progression-free survival (PFS) and disease response being secondary outcomes. Analysis of all 299 patients found a crude OS hazard ratio of 1.31 (95% confidence interval (CI), 1.00-1.71) for each additional 20% infusion received in the evening. A greater number of evening infusions was also associated with reduced PFS at 40% (95% CI, 30-54%) compared to those with fewer at 56% (95% CI, 50-63%). Disease response was also reduced in patients with more evening infusions (22%) compared to those with fewer (34%). Using a propensity score-matched analysis and multivariable adjustment, infusions in the evening were associated with a decreased OS (HR 2.04, 95% CI, 1.04-4.00, p = 0.038). Five year OS for patients receiving at least 20% of their treatment in the evening was 49% (95% CI, 31-76%) compared to 68% (95% CI, 53-86%) for patients with fewer than 20%. During treatment, 18% of 299 patients experienced colitis, 9% experienced hepatitis, and 5% had hypophysitis. No treatment related-deaths were recorded.

Image: PD

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: advanced melanomachronotherapyimmune checkpoint inhibitors (ICI)
Previous Post

Initial therapy with non-pharmacological agents may be preferable for lower back pain

Next Post

Evorpacept as single-agent or combination pembrolizumab or trastuzumab shows promise in the treatment of advanced solid tumours

RelatedReports

#VisualAbstract: Adjuvant Dabrafenib plus Trametinib Improves Outcomes in Stage III Melanoma
StudyGraphics

#VisualAbstract: Adjuvant Dabrafenib plus Trametinib Improves Outcomes in Stage III Melanoma

July 3, 2024
#VisualAbstract: Neoadjuvant Nivolumab and Ipilimumab Improve Outcomes in Resectable Stage III Melanoma
Chronic Disease

#VisualAbstract: Neoadjuvant Nivolumab and Ipilimumab Improve Outcomes in Resectable Stage III Melanoma

June 18, 2024
Stereotactic radiosurgery promising for patients with multiple brain metastases
Oncology

Atezolizumab, Vemurafenib, and Cobimetinib in Melanoma With CNS Metastases

October 9, 2023
#StudyGraphics: Atezolizumab in combination with vemurafenib and cobimetinib improve progression-free survival in patients with BRAFV600-advanced melanoma
StudyGraphics

#StudyGraphics: Atezolizumab in combination with vemurafenib and cobimetinib improve progression-free survival in patients with BRAFV600-advanced melanoma

April 28, 2023
Next Post
Age and number of islet autoantibodies associated with diabetes risk

Evorpacept as single-agent or combination pembrolizumab or trastuzumab shows promise in the treatment of advanced solid tumours

UTI associated with increased risk of preeclampsia

Increased cardiorespiratory fitness may lower high blood pressure in children

Intrapartum serum prolactin may predict risk of postpartum diabetes

Lowering systolic blood pressure with antihypertensives may reduce new-onset type 2 diabetes

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Intravaginal conjugated oestrogen does not improve continuation rate of ring pessary use
  • Artificial intelligence based clinical decision systems are safe and effective for diabetes management
  • Epic Launchpad propels generative-AI into everyday hospital routines
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.